-
4 weeks ago | 
healio.com | Regina Schaffer |Richard Smith |Mary Walsh |Amish N. Raval
Key takeaways: Select adults with ischemic heart failure with reduced ejection fraction may derive benefit from an investigational cell therapy. A new trial will commence for patients with HFrEF and elevated NT-proBNP. CHICAGO — An autologous point-of-care cell therapy for adults with ischemic HF with reduced ejection fraction was safe and may be beneficial for select candidates, though a pivotal study did not meet its primary efficacy outcome.
-
4 weeks ago | 
healio.com | Shawn M. Carter |Richard Smith
Key takeaways: An Oklahoma acute care hospital had a 400% increase in dialysis treatment volume during 9 months. Average successful dialysis treatment completion rate grew from 73.7% to 97.5% during the study. BOSTON — Switching to an in-house dialysis model may support health care facilities in care efforts and lead to high quality outcomes for patients, according to study data.
-
4 weeks ago | 
healio.com | Erin T. Welsh |Richard Smith
Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that tafamidis use in conjunction with acoramidis use did not alter the primary efficacy endpoints of the ATTRibute-CM study. Daniel P.
-
4 weeks ago | 
healio.com | Erik Swain |Richard Smith |Maria A. Pabon
Key takeaways: Finerenone reduced risk for new-onset atrial fibrillation vs. placebo in a pooled analysis. The patient population included those with certain kinds of heart failure and those with diabetic kidney disease. CHICAGO — Finerenone prevented new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes or heart failure with mildly reduced or preserved ejection fraction, according to new data from FINE-HEART.
-
4 weeks ago | 
healio.com | Erin T. Welsh |Richard Smith
In this video, an expert discusses study results presented at the American College of Cardiology Scientific Session that assessed sex-based differences observed in end-stage kidney disease after heart transplant. Elena M. Donald, MD, cardiology fellow at Columbia University Irving Medical Center, noted how women have an increased risk for developing end-stage kidney disease after heart transplant compared with men.
-
1 month ago | 
healio.com | Erik Swain |Richard Smith
Key takeaways:A transcatheter aortic valve replacement system designed to treat aortic regurgitation exceeded its safety and performance goals. A randomized controlled trial comparing TAVR with surgery is planned. CHICAGO — For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system exceeded safety and performance goals, according to results of the ALIGN-AR trial.
-
1 month ago | 
healio.com | Michael Monostra |Richard Smith
Key takeaways: Multiple predictors were linked to biochemical or structural evidence of disease 1 year after papillary thyroid microcarcinoma diagnosis. Risk stratification should be used to guide management of small tumors. Rather than tumor size alone, the American Thyroid Association’s risk stratification system should be used when assessing papillary thyroid microcarcinomas, according to data published in The Journal of Clinical Endocrinology & Metabolism.
-
1 month ago | 
healio.com | Scott Buzby |Richard Smith |Garima Sharma
Key takeaways: Adverse pregnancy outcomes do not entirely explain the link between prepregnancy obesity and CVD risk. Weight management before pregnancy may reduce excess risk for heart disease. Gestational diabetes and hypertensive disorders of pregnancy mediated only a small part of the association between women’s midlife heart health and prepregnancy obesity, researchers reported.
-
1 month ago | 
healio.com | Jill Rollet |Richard Smith
Among the top three barriers to home dialysis, cited independently by both patients and clinicians, is the need for home-based support, according to data published in the American Journal of Kidney Disease in 2024. The most recent USRDS Annual Data Report shows 14.5% of U.S. patients with end-stage kidney disease use home dialysis.
-
1 month ago | 
healio.com | Erin T. Welsh |Richard Smith
Key takeaways:RNA therapeutics lowered all-cause mortality, increased 6-minute walk distance and improved quality of life. RNA therapeutics also decreased brain natriuretic peptide levels and global longitudinal strain. CHICAGO — RNA therapeutics improved survival, 6-minute walk distance and quality of life for patients with transthyretin amyloid cardiomyopathy, according to study results presented at the American College of Cardiology Scientific Session.
